Item 2.02 Results of Operations and Financial Condition.

On January 18, 2022, Kevin Helash, the Chief Executive Officer of Marrone Bio Innovations, Inc. (the "Company") issued a letter to the Company's shareholders (the "Letter to Shareholders") announcing certain preliminary financial results for the fourth-quarter and fiscal year ended December 31, 2021, noting that the Company expects to report complete fourth-quarter and full year 2021 financial results in March 2022 and that the Company expected revenue growth and gross margins for the full year 2021 would be in line with forecasts. A copy of the Letter to Shareholders is attached as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

In addition to the matters addressed in Item 2.02, the Letter to Shareholders discussed product orders, advancements made in certain key products in the Company's research and development pipeline, and certain other matters.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number                      Description
     99.1          Letter to Shareholders dated January 18, 2022.

© Edgar Online, source Glimpses